Nivolumab
(asked on 18th January 2016) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what information his Department holds on the effects of nivolumab on one year survival rates for lung cancer.
This question was answered on 29th January 2016
Nivolumab is currently marketed in the European Union under the brand name Opdivo.
The data available when Opdivo was licensed in 2015 indicated overall survival among patients given the product was around nine months, whereas among the patients given docetaxel, another cancer medicine, it was six months.